Search Results - T. B. Pecherina

  • Showing 1 - 17 results of 17
Refine Results
  1. 1

    Biomarkers of myocardial fibrosis and their genetic regulation in patients with heart failure by T. B. Pecherina, A. G. Kutikhin

    Published 2020-11-01

    Currently, the development of chronic heart failure (CHF) is considered from the perspective of pathological structural remodeling of myocardium and fibrosis. Despite the widespread use of molecular genetic markers in clinical practice, only a small number of them are used to evaluate remodeling pro...

    Full description

    Get full text
    Article
  2. 2

    Clinical and prognostic significance of matrix metalloproteinases in patients with myocardial infarction by T. B. Pecherina, O. L. Barbarash

    Published 2019-06-01

    Biomarkers are often used as a surrogate measure in the assessment of risk, severity, and prognosis of the disease. For the optimal use of biomarkers in predicting cardiovascular risk, they should demonstrate reproducibility in sequential quantitative measurements and show high sensitivity and speci...

    Full description

    Get full text
    Article
  3. 3

    Modern ways to reduced mortality of myocardial infarction. What should be done? by O. L. Barbarash, T. B. Pecherina

    Published 2023-10-01

    Myocardial infarction is a formidable manifestation of coronary artery disease and accounts for one third of deaths associated with coronary disease. In Russia, from 400 to 500 thousand patients with acute coronary syndrome are hospitalized annually, about half of them with myocardial infarction (MI...

    Full description

    Get full text
    Article
  4. 4

    The role of matrix metalloproteinases in left ventricular remodeling in patients with ST-segment elevation myocardial infarction by T. B. Pecherina, O. V. Gruzdeva, O. L. Barbarash

    Published 2019-06-01

    Aim. To assess the role of matrix metalloproteinases (MMPs) in pathological remodeling of the left ventricular myocardium in patients with ST-segment elevation myocardial infarction (STEMI).Materials and Methods. We recruited 175 consecutive patients with STEMI (average age 61.3 (range 47-89) years,...

    Full description

    Get full text
    Article
  5. 5

    Antifibrotic effects of sodium-glucose cotransporter 2 inhibitors in patients with heart failure by Yu. S. Ignatova, S. U. Shuster, T. B. Pecherina, O. L. Barbarash

    Published 2024-02-01

    Heart failure (HF) is an urgent public health problem worldwide. A fundamental role in HF progression is played by fibrosis, which causes structural myocardial and vascular changes. In this regard, it seems relevant to search for pathogenetically justified HF therapy, aimed at slowing the myocardial...

    Full description

    Get full text
    Article
  6. 6

    EFFECT OF STATINS ON SERUM CONCENTRATION OF INFLAMMATORY MARKERS AND MATRIX METALLOPROTEINASES IN PATIENTS WITH ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION by TAMARA B. Pecherina, OLGA V. Gruzdeva, OLGA L. Barbarash

    Published 2019-03-01

    Aim. To assess the effect of pre-hospital administration of statins on the levels of inflammatory markers and matrix metalloproteinases in the se-rum of patients with acute ST-segment elevation myocardial infarction (STEMI).Materials and Methods. We consecutively recruited 175 patients with STEMI (1...

    Full description

    Get full text
    Article
  7. 7

    Challenges in managing adherence in patients with cardiovascular disease (review) by Yu. S. Ignatova, Ya. I. Bryukhanov, T. B. Pecherina, O. L. Barbarash

    Published 2025-01-01

    Cardiovascular diseases (CVD) remain one of the main problems in most countries of the modern world. In this connection, maintaining adherence to the treatment and prevention of CVD is a priority in the fight against diseases of the cardiovascular system. According to the WHO, insufficient adherence...

    Full description

    Get full text
    Article
  8. 8

    Actual Issues of Ischemic and Hemorrhagic Events Risk Management During Antithrombotic Therapy in Patients with Acute Coronary Syndrome by R. M. Velieva, T. B. Pecherina, A. S. Vorobiev, V. V. Kashtalap, D. Yu. Sedykh

    Published 2020-12-01

    Today, optimal duration of double antiplatelet (DAPT) and triple antithrombotic therapy (TATT) in patients with acute coronary syndrome (ACS) remains the subject of scientific and practical discussion on possibilities of ischemic and hemorrhagic risks assessment. Good clinical risk metrics is based...

    Full description

    Get full text
    Article
  9. 9

    Clinical and anamnestic characteristics of patients depending on left ventricular ejection fraction: results of a register study by P. G. Parfenov, A. V. Yurkina, D. P. Golubovskaya, S. Y. Shuster, E. V. Dren, Y. I. Guselnikova, N. B. Lebedeva, T. B. Pecherina

    Published 2024-07-01

    Aim. To study the clinical and anamnestic features of patients followed up in the Center for Chronic Heart Failure at the Regional Vascular Center according to the data of the corresponding register.Materials and methods. The study included data of 802 patients included in the Kuzbass Register of Pa...

    Full description

    Get full text
    Article
  10. 10

    Echocardiographic correlates of cardiac fibrosis in patients with myocardial infarction and preserved left ventricular ejection fraction by N. V. Fedorova, A. I. German, A. N. Kokov, N. K. Brel, T. B. Pecherina, V. V. Kashtalap, V. N. Karetnikova, O. L. Barbarash

    Published 2019-06-01

    Aim. To identify the possibilities of echocardiography in the evaluation of myocardial fibrosis inт patients with ST segment elevation myocardial infarction (STEMI).Materials and Methods. We recruited 70 consecutive patients who have undergone percutaneous coronary intervention due to STEMI. Echocar...

    Full description

    Get full text
    Article
  11. 11

    Serum markers of cardiac fibrosis suffering from heart failure with preserved left ventricular ejection fraction upon ST-segment elevation myocardial infarction by A. V. Оsokina, V. N. Karetnikova, O. M. Polikutina, O. V. Gruzdeva, T. P. Solodilova, S. N. Kosareva, A. V. Motova, T. B. Pecherina, O. L. Barbarash

    Published 2021-09-01

    Aim. Currently, there is no method which accurately predicts an adverse outcome of heart failure with a preserved left ventricular ejection fraction (HFpEF) upon ST-segment elevation myocardial infarction (STEMI). Here we studied the prognostic significance of procollagen type I C-terminal propeptid...

    Full description

    Get full text
    Article
  12. 12

    Molecular markers of cardiac fibrosis after myocardial infarction by O. L. Barbarash, A. G. Kutikhin, T. B. Pecherina, R. S. Tarasov, V. V. Kashtalap, N. V. Fedorova, L. A. Bogdanov, O. N. Hryachkova, D. Yu. Sedykh

    Published 2022-03-01

    Aim. To perform a screening for molecular markers of cardiac fibrosis upon myocardial infarction.Materials and Methods. We carried out echocardiography-guided endomyocardial biopsy of affected and intact interventricular septum segments of 7 patients with anterior myocardial infarction. Fibrotic and...

    Full description

    Get full text
    Article
  13. 13

    Participation of the C-terminal propeptide procollagen type I in the formation of cardiofibrosis in patients with myocardial infarction with preserved left ventricular ejection fra... by A. V. Osokina, V. N. Karetnikova, O. M. Polikutina, A. V. Ivanova, T. B. Pecherina, O. V. Gruzdeva, Yu. A. Dyleva, A. N. Kokov, N. K. Brel, O. L. Barbarash

    Published 2021-03-01

    Aim. To study the dynamics of procollagen type I carboxy-terminal propeptide (PICP) with an assessment of potential associations with cardiac fibrosis (CF) and diastolic dysfunction (DD) of the left ventricle (LV) during the hospitalization and one year after ST segment elevation myocardial infarcti...

    Full description

    Get full text
    Article
  14. 14

    Type 2 myocardial infarction: the potential for early detection by V. N. Karetnikova, A. V. Motova, A. V. Osokina, D. P. Golubovskaia, I. R. Oleinik, E. A. Schmidt, I. I. Zhidkova, T. B. Pecherina, O. M. Polikutina, O. L. Barbarash

    Published 2023-04-01

    Aim. To evaluate the potential of using factors associated with type 2 myocardial infarction (MI) for its early diagnosis.Material and methods. This prospective study included 204 patients diagnosed with acute coronary syndrome (ACS). At the time of admission, each patient underwent standard examina...

    Full description

    Get full text
    Article
  15. 15

    Predictors of myocardial fibrosis and loss of epicardial adipose tissue volume in the long-term period after myocardial infarction by O. L. Barbarash, O. V. Gruzdeva, T. B. Pecherina, O. E. Akbasheva, D. A. Borodkina, V. V. Kashtalap, V. N. Karetnikova, A. N. Kokov, N. K. Brel, Yu. A. Dyleva, E. V. Belik, E. G. Uchasova, E. E. Bychkova, A. A. Kuzmina

    Published 2020-03-01

    Aim. To assess the changes of biochemical markers in hospitalization, the relationship with the severity of myocardial fibrosis and the epicardial adipose tissue (EAT) thickness one year after myocardial infarction (MI).Material and methods. A total of 88 patients (65 men and 23 women) with MI were...

    Full description

    Get full text
    Article
  16. 16

    10-year experience in orthotopic heart transplantation in Kuzbass by L. S. Barbarash, O. L. Barbarash, E. V. Grigoriev, D. L. Shukevich, T. B. Pecherina, M. G. Zinets, A. V. Sotnikov, I. K. Khalivopulo, T. S. Golovina, E. M. Kurguzova, A. V. Ivanova, Yu. S. Ignatova, A. V. Yurkina, D. P. Golubovskaya, P. G. Parfenov, J. I. Gusel’nikova, E. V. Dren’

    Published 2025-01-01

    Background. Orthotopic heart transplantation (OHT) is the gold standard treatment for individuals with endstage heart failure (HF), providing the best survival and quality of life. In Russia, the number of OHT procedures and transplantation of other organs have significantly increased in recent year...

    Full description

    Get full text
    Article
  17. 17

    Non-immunogenic staphylokinase — a thrombolytic agent in the treatment of massive pulmonary embolism: results of the FORPE clinical trial by A. I. Kirienko, S. G. Leontyev, E. B. Yarovaya, S. I. Konstantinov, B. B. Orlov, Imad Meray, D. V. Duplyakov, V. E. Oleynikov, E. Yu. Vasilyeva, E. A. Ponomarev, S. A. Pribylov, A. G. Komarova, V. V. Bobkov, R. M. Rabinovich, G. V. Klein, Z. S. Shogenov, Yu. V. Karabach, V. N. Zolkin, V. V. Kulabukhov, V. V. Kashtalap, K. A. Linev, G. I. Stryabkova, N. V. Yasnopolskaya, V. Yu. Tolmacheva, Zh. Yu. Chefranova, Yu. A. Lykov, E. S. Panina, N. V. Solovieva, E. V. Rybin, N. V. Furman, E. V. Kulibaba, V. V. Makukhin, A. G. Koledinsky, I. S. Mullova, N. A. Cherepanova, T. V. Pavlova, P. P. Savvinova, I. A. Libov, A. S. Igoshin, I. Yu. Bogomazov, T. B. Pecherina, L. O. Lyudnev, P. N. Vlasov, I. V. Avdeeva, D. B. Maksimov, E. V. Komissarova, V. S. Ivanov, N. L. Vyazova, E. V. Vyshlov, D. S. Kurtasov, V. A. Kutsenko, O. E. Ivlev, A. G. Soplenkova, S. N. Tereshchenko, I. S. Yavelov, R. M. Shakhnovich, A. D. Erlikh, O. B. Talibov, A. M. Semenov, M. P. Semenov, S. V. Ivanov, Yu. A. Romashova, V. V. Beregovykh, A. I. Archakov, S. S. Markin

    Published 2024-12-01

    Aim. To assess the safety and efficacy of a single intravenous bolus of non-immunogenic staphylokinase compared with alteplase in patients with massive pulmonary embolism and hemodynamic instability. Non-immunogenic staphylokinase is a modified recombinant staphylokinase with low immunogenicity, hig...

    Full description

    Get full text
    Article